Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Doc83 -
I'd be particularly interested in what the exec they hired, who I remember had an excellent track record in pharma mass production/ quality control has been doing for the last two years.
I imagine he's European wordle champion by now and it's a safe bet he could solve the rubiks cube quicker than you and I. :)
As DocD said, they've bunkered down and I doubt they'll come out until they have p2 trial news to share.
I no longer have a problem with that, as we can only be concerned about what we can control.
Simply a waiting game now.
Doc83 -
Re your 20.34 last evening - It was me who originally used that quote regarding one of the basic duties a CEO should fulfil.
At the time I said we didn't need to know what biscuits were on the tea trolley etc, we don't need our hands holding, but a quarterly update on progress should come as standard.
Apparently not anymore.
I totally understand our capital was spent a long time ago and we are now surplus to requirements and the AGM is merely a 'fly in the ointment' so to speak, but a basic update every 3 months is surely not too much to expect.
Totally agree with you regarding a possible future placement. I don't see a rush to fill the begging bowl this time, having kept radio silence for so long.
Still positive we'll get a result somewhere down the line though.
ATVB.
'I think his purpose is to annoy other people and get reactions.'
'Moderation on this site is awful btw'
Two quotes today from the individual who told one LTH to 'f*ck off' and called another 'a dick'.
You can't make this stuff up, better than the telly.
Doc83 –
Apologies if I misinterpreted your post on Saturday evening re your thoughts on future price targets.
I think this share has aged us all over the years to some extent Doc, membership of LSE should come with a free blood pressure monitor, that’s for sure. At least we’re not invested in SYME, to my knowledge the most over hyped AIM stock in history.
TomD –
‘Interesting that the calculation of the companies worth starts from multiples of 6p’.
Where else could I start from? That’s the logical starting point as it's roughly my new average, as I said I’ve been building yet another position from around that figure, having lost a small fortune along with everyone else back on that truly awful February day in 2020, having previously made a small fortune in the summer of 2020 when promising P2 results were announced.
Ce la vie.
I've been in and out several times in between taking smaller profits, as I prefer this style of investing, even though it takes more time and effort than simply using 'buy and hold'.
I haven't posted for over eight months until now, as there simply hasn't been anything material to discuss.
Hopefully that will change sooner rather than later, but I'm quite prepared to wait as long as it takes.
Reading this page every day as I do, I realise that puts me in the minority.
Doc83 – Saturday evening @ 8.36 – ‘There’s an argument to suggest why shouldn’t we get to £10+.’
This week marks four years since I began reading this page. I bought my first tranche of shares three weeks later.
I have seen many posters come and go in that time – You are one of the more honest and reliable posters that always gives a decent summary of the current position.
As it is Saturday evening Doc and this is the ‘happy time’ of the week, I’ll give you the benefit of the doubt and call the above quote ‘the exuberance of youth’. I’m guessing from your username you may be at the tender age of 41ish.
Post - potential successful P3 results:
Bearing in mind we are no longer in the middle of a covid pandemic and we will most likely have a JV in place that almost certainly won’t be in SNG’s favour, I would put forward the suggestion that ‘The argument to suggest £10’ is either weekend wishful thinking or possibly alcohol fuelled.
6p to £10 = x166 bagger.
Take a look at this video from 7 years ago back in the day when a clean shaven Richard Marsden actually talked face to face with potential shareholders (If only).
This is when SNG were schmoozing retail investors around the UK, attempting to prise that hard earned folding out of individual bank accounts, promoting a potential circa 25p to £40 = x160 bagger (seriously?).
Scroll to 13.30 minutes and watch for a couple of minutes:
https://www.youtube.com/watch?v=BzK7lCjN6Jw
The poster ‘Dactions’ (sadly no longer posting here) was in attendance and was convinced by RM’s presentation, much to his regret.
My father who taught me stock market fundamentals, advised me to half and half again any figure quoted by any company director trying to accumulate seed capital. Marsden alluded to £40, so I pencilled down a possible £10 = 40 bagger.
Today, the endgame absolute best case scenario for me at this level now would be 6p x 40 = £2.40. Anything above this would be dreamland, a more realistic view in my opinion would be between £1 - £2, depending on market conditions.
During Dec + Jan I’ve steadily been building yet another significant holding in SNG, as for me 6p represents the near bottom of an unloved stock that has huge potential, but I believe the days of £10+ have sadly long gone with Sprinter.
If P3 results are favourable a figure above the placing price of £1.75 would not be out of the question.
As an aside Doc, I hope you took the hint last summer regarding AGL when you made enquiries on that board. 10p to 31p inside two days last month was well worth waiting for, I hope you were on board.
ATVB T.
It's the end of 'dry January'.
It hasn't been easy - 31 evenings of drinking nothing but sauvignon blanc.
Just a touch of mild humour to add balance to a very toxic board.
Yes DocD, inhaled as opposed to intravenous is definitely the way to go, as Faron pharma found out to their cost during their covid trials.
Trial and error....trial and error....trial and success. Takes a decade or two, but we're close to the 'beginning of the end' regarding the science now. We may have to wait until the end of H1, I don't have a problem with that, but some investors seem more impatient than others.
T
Interesting nugget of information from the Polarean Imaging (POLX) December RNS:
‘Polarean has signed contracts to sponsor a new clinical trial in patients with COPD (chronic obstructive pulmonary disease) in collaboration with a leading nebuliser device manufacturer. The pilot study will explore the use of XENOVIEW MRI as the primary outcome measure in the evaluation of different aerosol drug delivery technologies of albuterol, a bronchodilator.’
Good to see research in respiratory illness is still ongoing in these trying times. Hopefully SNG will be issuing a similarly encouraging message to long suffering shareholders sooner rather than later.
Given the toxicity of this page at present, I would add a caveat that the above company is not a ramp or recommendation, simply relevant background information on yet another quiet day.
T
From the summer of 2023 –
Xviolet:
‘I have been warmed and inspired by how so many of us keep on posting and manage to be reasonably kind with each other.’
Can you get me some of those drugs Xv - Pleeease.
T
Rebs438 -
Post of the week. Although that award is not difficult to achieve on this board at present.
This, from one of the 30 or so long term members on here who have seen this board invaded by the recent price action.
Seen this so many times over the years on LSE, should go quiet as the price drifts further South before the next leg up.
Researcher1 -
Please stop showing off, it puts you in a very bad light - we're all making good money here, but with no way of proving the figures there's no point posting actual numbers.
Take your profit quietly, wait for the prostate RNS and then make some more, but please stop being smug, I thought you were better than that.
May offset some of those SNG losses Doc!
Medium to long term hold for me - dare I use the phrase 'bottom drawer stock'?!
Patience and more patience required with these junior pharmas.
Good to see you and GG climbing aboard.
ATVB T.
Hi Doc, good to see you posting here.
I've bought and sold these over the last 2 - 3 years and am buying again at these levels, as I struggle to believe this won't be eventually bought out at some stage.
AGL shares similar traits to one of your other holdings SNG (and also POLX and PHE to some extent, along with several other AIM shares) in that there is a novel product/ technology, but zero commercial acumen within the boardroom, although the recent changes here may alter that going forward - time will tell.
There was a recent online Q+A session with the CEO here, where he actually smirked at one of the pi questions, his arrogance, poor public relations and inability to commercialise has done nothing for the share price and LTHs currently sit in limbo waiting for news, as is often the case with this type of share.
I wish you and all other holders nothing but the best, whatever you decide.
I read this and a handful of other boards on a daily basis, but have deliberately stopped contributing for a while, as there is very little constructive to add at present.
ATVB T
'We just want to know how we’ll recognise YOU?'
He'll be the one in the straightjacket with the warden next to him.
He said he was a regular company 'insider' - I think the meaning was lost in translation,
probably meant he'd been 'inside' more than once.
Aether:
Re your post from last evening, ‘How much will this rise?’
To answer that question, you need to look to the past:
17/07/20 – 36p
One week later
24/07/20 – 203p = + 460%
A month later when the ‘late money’ came in
21/08/20 – 246p
Bear in mind this was in the middle of a global panic when so-called ‘covid stocks’ were all the rage.
This rise was on the back of P2 results and many investors thought SNG would be fast tracked to stardom on the back of an EUA.
The next inflection point(s) can only occur with Strive inclusion and/ or P3 announcement, I doubt the recently announced studies will move the share price to any significant level.
Successful Strive/ P3 results for a novel broad spectrum anti-viral will see + 460% and then some – But from what level?
If Marsden does his job and gives regular upbeat messages (unlikely) to market then maybe this will move up from a decent baseline, if not this will wallow in single figures.
Get the tea leaves out for that one Aether.
Fruits is holding out for £7.
Richard Marsden is hoping SNG will be taken out for circa £40 (unlikely).
Take your pick.
If Strive/ P3 fails (unlikely) SNG will likely be de-listed from AIM and taken into private hands.
One for the patient investor who can filter out the daily LSE ‘noise’ from the menagerie for another 2 -3 years, not for the faint hearted.
Dictionary definition - ‘Menagerie - A strange or diverse collection of people or things’.
ATB T
Well that didn’t take long.
https://apnews.com/article/first-republic-bank-silicon-valley-fdic-5ab48702b7136d42f73ac13e0a20955d
Taken over the same day by the shadiest of all US financial institutions JPM, in order to avert panic in the markets.
For me, the most salient comment in all the articles covering this story is:
‘The bank’s shareholders are likely to be wiped out as part of the deal’.
No surprise there. I doubt this will be the last.
Biden says the US banking system is ‘safe and sound’. Are you reassured by that? – Ermm…
Why is this relevant?
Macro events like this trickle down to affect micro markets around the world, including AIM.
Sorry to say, this is not going to be an easy ride for any of us this year.
ATVB T
So what did we learn this week?
Richard Marsden is still alive.
This is a bottom draw stock.
No need for an EGM, as there are funds available for the foreseeable.
SNG continue to ‘go it alone’ (more or less).
There is no SPAC on the horizon.
Annual financials RNS don’t include detailed plans, only a ‘broad brush’ summary of the year and outlook.
Meat on the bone will follow separately in due course.
99% of this board knew most of the above before the latest RNS.
So what else is confirmed?
They have a plan.
They have a deep understanding of the mechanism of how their drug works.
They know exactly which patient types to treat.
They know at what stage to use the treatment.
In other words, after two decades of research/ studies/ trials, the science is nearing completion.
If you like to play the ‘hokey cokey’ with your shares (in out, in out) Friday was a good day to sell, as the price will begin to drop steadily once more, as yet another period of silence begins.
The only thing that could possibly catch you out is Strive inclusion, but as a melting glacier moves faster than the staff at Strive this is unlikely anytime soon.
A good opportunity to average down yet again, there have been several over the past year or so if that’s your style of investing.
If not, expect a Spring/ early Summer lull, as details of the new studies will probably be announced and conducted in the Autumn/ Winter months.
No doubt their will be an RNS informing us the luminaries at SNG are beginning lap 2 of their global presentation jaunts soon.
There will be the usual ‘copy and paste’ comments from the usual posters expressing their displeasure.
I’m still in no doubt that this drug will eventually reach the lungs of those poor souls who need it and we will eventually reap the rewards. The key word here is ‘eventually’ and as the average AIM investor’s attention span seems to be 3-6 months, nerves of steel will be required, especially if you read the comments on this page on a daily basis.
Finally, the online mentors that I follow are all advising that at some point in the not too distant future, you and I will have to deal with the small matter of another global financial crash, due in no small part to the looming liquidity and banking crisis, which will dwarf the Lehmann Brothers episode.
I’m told another US bank will fail shortly, with the accompanying bail out to follow.
More on this another time.
Put this on the back burner and enjoy the rest of your bank holiday, mine is already over, back to it tomorrow for me.
ATVB T
Doc83 – Re your 16.20:
It was me who quoted Geraint Anderson, as I thought his view would carry more weight coming from an actual CEO than a mere retail investor like myself.
That post was some months ago, when I thought Marsden hadn’t given an update for some time – Still waiting!
No remaining SNG investors need their hands holding, but we should be updated with progress (or lack of) every quarter as a minimum. This isn’t impatience as some have implied, to me it’s a matter of respect for those who handed over their hard earned folding to help get the company where they are today.
We all know how AIM works, in the initial stages of development the CEO will court investors with the juicy financial carrot at the end of the stick, in order to accumulate seed capital. They appear regularly at investor events/ presentations and are quite willing to chat to you face-to-face if they think they can prise a few quid out of your hands.
Marsden’s carrot had a £40 sticker on it at the time, the BOD spend the money on research and then put you down the pecking order of importance. I don’t have a problem with that, as that’s the nature of AIM companies.
Seasoned investors will have taken 75% off his carrot and weighed the risk/ reward ratio. Circa 50p to £10 for a drug that showed obvious promise, but at the time didn’t have significant trial results to back it up seemed a decent speculative investment to me at the time – anything else would have been a bonus.
I took the bait back then in a major way, the poster ‘Dactions’ was in well before then, the very essence of a ‘long term holder, never sold a bean’ investor. He was present at the presentation on the link below where Marsden offers the bait (scroll to 13.30 mins and watch for 60 seconds).
I think Dactions and those who invested in the early days deserve something, anything to keep them in the loop.
I doubt any of us are holding our breath for a paradigm shift, but something concrete to ponder over would be better than the vacuum we have at present.
Many thanks for your regular contributions by the way, when I read this board during the early evening you and one or two others have already posted what I was thinking, so saving me the trouble!
https://www.youtube.com/watch?v=BzK7lCjN6Jw
ATVB T
EC - Could you ramp this up a bit more, you really aren't trying hard enough.
Only 6 posts this morning, no slacking on the afternoon shift now. :)
T
The general mood of the board and relentless ‘tit for tat’ bickering from the usual suspects is almost a mirror image of 2020 between March and July before positive results were announced.
Silence breeds uncertainty and that’s when the mind games come into play.
These are largely pointless, as this board is mainly made up of a mixture of LTHs who fundamentally believe in the company and science and will stick it out to the bitter end and also LTHs who are so underwater they cannot bring themselves to crystallise their loss, with a small mixture of undesirables in between.
Some of the names have changed, but it’s the same old same old. This is all looking a bit binary now, a lame (but not dead) duck or we’re off to the races again.
Thursday can’t come quick enough, this endless positive/ negative speculation by retail investors is painful to witness.
T